Unknown

Dataset Information

Management and mechanism of calciphylaxis in a patient treated with the FGFR inhibitor pemigatinib-a case report.


ABSTRACT:

Background

Small molecule fibroblast growth factor receptor (FGFR) inhibitors, such as pemigatinib, have been developed for the treatment of cholangiocarcinoma (CCA) with rearrangements or fusions in the FGFR2. FGFR inhibitors (FGFRis) have dermatologic side effects such as dry skin or nail bed damage. However, in very rare instances, a life-threatening vascular calcification disease known as calciphylaxis has been linked to these therapies.

Case description

We report a patient with metastatic CCA, who developed calciphylaxis following the start of their pemigatinib treatment. Calciphylaxis is associated with skin lesions and affects the dermal microvasculature in addition to the vascular calcification. This case focuses on the management strategy used for this rare adverse

SUBMITTER: Chandana SR 

PROVIDER: S-EPMC10932651 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature